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Background: Budd–Chiari syndrome (BCS) often leads to hepatocellular carcinoma (HCC). Transcatheter arterial
chemoembolization (TACE) has been increasingly used to treat BCS patients with HCC. The purposes of this study
were to illustrate imaging features in BCS patients with HCC, and to analyze the effects of TACE on BCS patients
with HCC.
Methods: 246 consecutive patients with primary BCS were retrospectively studied. 14 BCS patients with HCC were
included in this study. BCS were treated with angioplasty and/or stenting, and HCC were managed with TACE.
Imaging features on ultrasonography, CT, MRI, and angiography and the serum AFP level were analyzed.
Results: Inferior vena cava block and stricture of hepatic venous outflow tract more frequently occurred. Portal vein
invasion was found in only 2 patients (14.2%). Imaging studies showed that most nodules of HCC were near the
edge of liver, irregular, more than 3 cm in diameter, heterogeneous mass and solitary (≤3 nodules). HCC in patients
associated with BCS was isointense or hypointense in nonenhanced CT images, and exhibited heterogeneous
enhancement during the arterial phase and washout during the portal venous phase on enhanced CT and MRI. The
serum AFP level significantly declined after TACE treatment.
Conclusions: BCS patients with inferior vena cava block and stricture of hepatic venous outflow tract seems to be
associated with HCC. A single, large, irregular nodule with a peripheral location appears to be HCC. TACE can
effectively treat HCC in BCS patients.
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The Budd–Chiari syndrome (BCS) is a heterogeneous
group of disorders, which are characterized by hepatic
venous outflow obstruction at the level of the hepatic
venules, the large hepatic veins, the inferior vena cava
(IVC), or the right atrium. Obstruction of hepatic ven-
ous outflow tract leads to sinusoidal congestion, ische-
mic injury to liver cells, and portal vein hypertension,
subsequently leading to hepatic congestion with necro-
sis, regeneration, fibrosis, and liver cirrhosis [1-4]. Pa-
tients with BCS have been reported to be associated
with hepatocellular carcinoma (HCC), the most com-
mon form of primary liver malignancy [5,6]. Several lines* Correspondence: maoqiangwang234@163.com
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reproduction in any medium, provided the orof evidence have shown that cirrhotic process following
chronic hepatic congestion can result in the develop-
ment of HCC in patients with BCS after excluding the
influence of hepatitis viruses, alcoholism, autoimmune
diseases or chemical intoxication [4,7-10].
BCS and HCC are often diagnosed on the basis of
characteristic imaging findings on ultrasonography, CT,
and MRI in combination with the clinical situation
[6,11]. The serum a-fetoprotein (AFP) has also been
used for diagnosis and screening of HCC [12]. There is
an increasing acceptance of diagnosis of HCC using im-
aging techniques without biopsy [11,13,14]. However,
the imaging features of HCC in patients with BCS have
not been well established.
Several therapeutic options have been advocated to treat
HCC, including transcatheter arterial chemoembolizationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




Mean age (range) 44.69 years (27–60
years)
Duration of symptoms (range) 14.8 years (0.6-28 years)
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TACE has been widely used in the treatment of HCC by
interrupting the arterial supply to the tumor, thus leading
to ischemic tumor necrosis [15]. Focused administration
of chemotherapy during TACE increases the therapeutic
effects and decreases systemic side effects of chemother-
apy agents. TACE has been demonstrated to improve sur-
vival in patients with HCC, especially in patients with
unresectable HCC [16,17]. It has been reported that TACE
treatment results in an effective tumor response in about
60% of HCC patients associated with membranous ob-
struction of the inferior vena cava (MOVC) [9]. However,
the effects of TACE treatment in HCC patients with pri-
mary BCS have not been well established yet.
In this study, we retrospectively investigated 14 con-
secutive HCC patients associated with BCS who under-
went TACE treatment. The purpose of this study was to
analyze the imaging features of HCC and changes in the
serum AFP level after TACE treatment, to assess the risk
factors associated with HCC, and to evaluate effective-
ness of TACE treatment in these patients.
Methods
Patients
The study was approved by the Ethics Committee of
Chinese People’s Liberation Army General Hospital, and
all subjects gave their informed consent. We retrospect-
ively studied 246 consecutive patients with a primary
diagnosis of BCS, who were admitted to our hospital be-
tween March 1994 and May 2011. Date of diagnosis was
the date of the first investigation when the criteria for
diagnosis of BCS were fulfilled. Diagnosis of BCS
followed the criteria by the European Group for the
Study of Vascular Disorders of the Liver [6]. All patients
underwent ultrasonography, magnetic resonance im-
aging (MRI), computed tomography (CT), and/or angi-
ography, to examine the obstruction of hepatic veins,
portal vein and/or IVC. The diagnosis of BCS was based
on imaging showing an obstructed venous outflow tract.
All patients had occlusion or stenosis of the hepatic
veins and/or IVC. Patients with HBV and HCV infec-
tion, a history of alcoholism and chemical intoxication,
and autoimmune diseases were excluded from this study.
Fourteen BCS patients with HCC and fifty-one patients
with benign nodules were included.
The diagnosis of HCC was followed the criteria by
European Association for the Study of the Liver criteria
for the diagnosis of hepatocellular carcinoma [11]. The
diagnosis of HCC was based on imaging features on
ultrasonography, CT and/or MRI and the serum AFP
level [12,18]. Liver nodules were evaluated according to
the following imaging features: shape, number, size, loca-
tion, enhancement on arterial phase, washout on portal
venous phase, tumor thrombus of the portal vein, andlung metastasis. All 246 patients underwent ultrasonog-
raphy, 161 patients underwent enhanced MRI, and 85
patients underwent enhanced CT. Nodules were biop-
sied routinely if nodules had the at least one of the fol-
lowing features: 1) ≤ 3 in number; 2) ≥ 3cm in diameter,
3) heterogeneity; 4) washout on portal venous phase; 5)
changes in on two successive imaging during the follow
up period of at least 1 year; and 6) increase in the serum
AFP levels. Benign nodules were considered when nod-
ules had none of the above features, or malignancy was
ruled out by histological examinations of the biopsied
nodules. A nodule with two typical imaging features and
a serum AFP level greater than 400 μg/L were the diag-
nosis criteria for HCC. Biopsies of liver nodules were
performed to confirm the diagnosis of HCC. Table 1
summarizes the major clinical information of these 14
patients.
Imaging
Computer tomography (CT) was performed by a 16-
slice spiral CT scanner (GE LightSpeed). Nonionic radio-
graphic contrast medium Ultravist or Omnipaque (90–
100 ml) was administered intravenously at the rate of 3.5
ml/sec. CT images were obtained during hepatic arterial
phase (25 sec after the injection of contrast medium)
and the portal venous phase (60 sec after the injection of
contrast medium). The magnetic resonance imaging
(MRI) was produced by a 1.5-T MRI device (GE signa).
MRI protocol included T1-weighted imaging (T1WI),
T2-weighted imaging (T2WI), and gadolinium-enhanced
MRI. After bolus injection of gadolinium-DTPA at a rate
of 2.5 ml/sec, gadolinium-enhanced MR angiography
were performed during arterial phase (14–16 sec after
the injection of contrast medium), the venous phase
(10–15 sec after arterial phase), and the parenchymal
phase (120–150 sec after venous phase).
Untrasonograms were obtained with a 1024 × 1024
matrix at a frame rate of 3–6 sec by using a digital sub-
traction angiographic (DSA) unit (GE LCV Plus) and a
digital flat-panel system (INNOVA 3100/4100). Both
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and superior mesenteric angiography, a 4F catheter was
placed at the celiac artery and superior mesenteric artery,
and nonionic radiographic contrast medium Ultravist
(25 ml) was administered at the rate of 5 ml/sec. For in-
ferior vena cava angiography, a 4F inferior vena cava
catheter was placed at the hepatic segment of inferior
vena cava, and nonionic radiographic contrast medium
Ultravist (30 ml) was administered at the rate of 15 ml/
sec. For hepatic venous angiography, a Cobra, or Yashiro
catheter was placed at the hepatic vein, and nonionic
radiographic contrast medium Ultravist (9 ml) was ad-
ministered at the rate of 3 ml/sec.
Interventional treatment
Transcatheter arterial chemoembolization (TACE) were
performed after visceral vascular evaluation on the hep-
atic arterial anatomy, the arterial supply of the tumor,
and any ateriovenous shunting. Selective catheterization
of celiac artery-hepatic artery was performed by a 4F
catheter, and fluorouracil (500–750 mg) was adminis-
tered. Selective catheterization of branches of hepatic ar-
tery was achieved by a 3F microcatheter, and a mixed
solution containing epirubicin (20–50 mg), oxaliplatin
(100–150 mg), mitomycin (8-12 mg) and lipiodol (5–20
ml) was administered.
Occlusion or stenosis of inferior vena cava and hepatic
vein was treated with balloon catheter dilation. The bal-
loon catheter was inserted into inferior vena cava and
hepatic vein through femoral vein and/or jugular vein. A
balloon catheter of 20–25 mm in diameter and 40 mm
in length was used for inferior vena cava, and a balloon
catheter of 8–12 mm in diameter and 40 mm in length
was used for hepatic vein.
Follow-up
All patients underwent ultrasonography, CT and/or MRI
during the follow-up. Serum AFP was also tested during
the follow-up. The imaging features of HCC and the ef-
fects of treatment were evaluated.
Statistical analysis
Analyses were performed using SPSS 17.0. Quantitative
data were expressed as mean and range. Student t test
was used to compare the difference between before and
after treatment of quantitative data. Categorical data
were compared using the chi-squared test or Fisher’s




The clinical features of 14 HCC patients associated with
BCS are shown in Table 1. Eight (57.14%) of fourteenpatients were male, and six (42.86%) patients were fe-
male. The mean age was 44.69 years (range, 27–60
years). HCC was diagnosed with imaging features (ultra-
sonography, CT and/or MRI) and serum AFP level in 10
patients, and with histological examinations in 4 patients
after surgical removal of the nodule (biopsy for 2 pa-
tients, surgical resection for 1 patient, and liver trans-
plantation for 1 patient). The histological findings of the
four samples showed hepatocellular carcinoma and cir-
rhosis in adjacent parenchyma. The mean duration be-
tween diagnosis of BCS and HCC was 14.8 years (range,
0.6-28 years). Inferior vena cava block alone was found
in 57.14% (8/14) of patients, and hepatic vein and infer-
ior vena cava block was observed in 42.86% (6/14) of pa-
tients. Venous outflow tract stricture and obstruction
was found in 71.43% (10/14) and 28.57% (4/14) of pa-
tients, respectively.
The serum AFP level was normal in 2 patients with
HCC (1.86 μg/L and 15.09 μg/ L), whereas the mean
level was 5624.58 μg/L (range, 63.9–20000 μg/L) in the
other 12 patients. The tumor size was 5 cm and 3 cm
for the 2 patients with normal AFP level, whereas the
mean tumor size was 9.6 cm (range, 1.2-20 cm) in the
other 12 patients. In addition, benign nodules were
found in 51 patients with BCS. The serum AFP levels
were stable and normal (< 20 μg/L) in all these patients.
Portal vein invasion occurred in 2 of 14 HCC patients
associated with BCS. In contrast, portal vein invasion
was found in 129 of 200 HCC patients caused by hepa-
titis viruses. The frequency of occurrence of portal vein
invasion was significantly different between the two
groups of HCC patients (χ2 = 11.8611, P = 0.0006).
Imaging features of hepatocellular carcinoma
Diagnosis of BCS was based on ultrasonography, CT
and/or MRI (Figure 1, Figure 2A,B, Figure 3A,B). The
final diagnoses were based on angiography. HCC was di-
agnosed with CT in 10 patients and with CT and MRI in
4 patients, and was confirmed with DSA before TACE in
all 14 patients. Lung metastasis was found in 3 patients.
The imaging features of 14 patients are summarized in
Table 2. All patients with HCC had three or fewer nod-
ules, and 10 patients had only one nodule. The largest
nodule, usually located near the edge of the liver, was se-
lected to evaluate the size, location, and shape of the
nodule, if the patient had more than one nodule. Mean
size of the nodule was 8.75 cm (range, 1.2–20 cm) in
diameter.
Nonenhanced CT images showed that all 21 nodules in
the 14 patients with HCC were isointense or hypointense
relative to the surrounding parenchyma. The 20 nodules
exhibited irregular and heterogeneous enhancement on
the arterial phase. Only one nodule with tumor size of
1.2 cm (serum AFP level of 84.6 μg/L) showed a regular
Figure 1 45-year-old woman with HCC in BCS. (a) Contrast-enhanced transverse CT scan showing two large heterogeneous enhanced
nodules (⇨) in the right liver during arterial phase and enlarged caudate lobe (⇩), ventral varicosities (⇧), liver cirrhosis and mild ascites. (b) The
two nodules were given TACE. (c) The blocked inferior vena cava was given angioplasty. (d) CT scan showing that the nodules were obviously
shrinked and obtained stable effect after 4 TACE and 1 angioplasty during the 22-month treatment. Lipiodol was not located equably in
the nodules.
Figure 2 50-year-old man with HCC in BCS. (a) Contrast-enhanced transverse CT scan showing a large heterogeneous enhanced nodule (⇩) in
the left liver during arterial phase, and enlarged caudate lobe (⇨), cirsoid semi-azygous vein (⇦), and liver cirrhosis. (b) Washout of the nodule on
portal venous phase (⇩). (c) Angiography showing heterogeneous, contorted and enlarged tumorous vein and tumor staining in the left liver (⇦)
during arterial phase. TACE was given. (d) CT scan showing that the nodule was obviously shrinked and obtained stable effect 2 months after
TACE treatment. Lipiodol was not located equably in the nodule.
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Figure 3 51-year-old woman with HCC in BCS. (a) Contrast-enhanced transverse CT scan showing a large mild heterogeneous enhanced
nodule(⇦) in the left liver during arterial phase and obvious cirsoid azygous vein and semi-azygous vein (⇩) and liver congestive cirrhosis. (b)
Washout of the nodule on portal venous phase (⇦). (c) Angiography showing heterogeneous and contorted tumorous veins in the left liver (⇦)
during arterial phase. TACE was given at the first time. (d) Contrast-enhanced transverse CT scan showing that the nodule was obtained stable
effect after 2 TACE treatments for 14 months. Lipiodol was located equably in the nodule.
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venous phase occurred in all nodules, and a central scar
was not found in any nodules. Portal vein invasion was
found in 2 of 14 patients.
Axial T1-weighted MR images obtained during the ar-
terial phase showed that all nodules exhibited an irregu-
lar and heterogeneous enhancement. Axial T1-weighted
MR images obtained during the portal venous phase
showed that washout occurred in all nodules. On T2-Table 2 Imaging features of 14 HCC patients associated
with BCS
Imaging features Data
Liver cirrhosis (n) 14
Number of nodules 21
Mean size (range) 8.75 cm (1.2-20 cm)
Location (left lobe:right lobe) 8:6
Shape (irregular:regular) 11:3
Invasion of the portal vein 2
Lung metastasis 3
Nonenhanced phase Isointense or hypointense
Enhancement
Arterial phase Heterogeneous enhancement
Portal venous phase washout
The largest nodule was selected to evaluate the size, location and shape of
the nodule, if the patient had more than one nodule.weighted MR images, these nodules were hyperintense
or isointense.
In contrast, benign nodules were regular, homoge-
neous, numerous, and small, compared with nodules in
HCC. Only two benign nodules had a diameter of >3
cm. The benign nodules showed homogeneous enhance-
ment on the arterial phase and slight hyperintensity on
portal venous phase.
Cirrhosis was found in the adjacent parenchyma in all
patients with HCC, and in 56.9% (29/51) of patients with
benign nodules. There was a significant difference in the
occurrence of cirrhosis between patients with HCC and
patients with benign nodules (χ2 = 7.3041, P = 0.0069). In
addition, 43.1% (22/51) of patients with benign nodules
had hepatic congestion and hepatomegaly.
Treatment
The treatment of 14 patients with HCC is shown in
Table 3. Nine patients underwent angioplasty for hepatic
vein and/or inferior vena cava block. Stenting was
performed in one patient to treat inferior vena cava
block (Figure 1B,C). There were 25 TACE treatments for
the 14 patients (range, 1–4 times per patient) (Figure 1B,
C, Figure 2C, Figure 3C). One patient, who underwent
angioplasty and stenting 8 years ago, was treated with
TACE and angioplasty when HCC and recurrent inferior
vena cava stricture were found. Five patients underwent
angioplasty when they were treated with TACE at the
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they were treated with TACE at the second time. Four
patients were treated with only TACE. After TACE treat-
ment, three patients underwent radiofrequency treat-
ment, and two patients underwent surgical resection of
the tumor. One patient underwent liver transplantation
at 3 months after surgical removal of the tumor.
Fellow-up
All patients with HCC were followed up with an average
period of 33.46 months (range, 2–71 months) after
TACE. Lipiodol distributed in the HCC evenly in 12 of
14 patients (Figure 1D, Figure 2D, Figure 3D). One pa-
tient showed progression of HCC during the follow-up
period of 25 months after TACE. The other one lost to
follow-up after 2 months. The serum AFP level signifi-
cantly declined from 4760.57 μg/L before TACE treat-
ment to 60.13 μg/L during the follow-up period of >1
year after TACE treatment (t = 2.336, P = 0.0377).
Other patients without HCC were followed up for 1-
15 years (median, 7.8 years), and no HCC were found.
Discussion
HCC has been regarded as one of the major complica-
tions of BCS, and appears to develop chronically with
the progression of BCS [10,19]. The prevalence of HCC
in patients with BCS varies in different regions. The inci-
dence is high in Japan (41%), South Africa (48%), and
the United States (25%) [20-22]. The incidence in China
has not been reported. In this study we found that the
cumulative incidence of HCC was 5.69%, which was
lower than that reported in Japan, South Africa and the
United States. The incidence of HCC in patients with
BCS is similar to that in patients with other chronic liver
diseases (4–17%) [23].
The accurate pathogenesis of HCC in patients with
BCS has not been elucidated. It is believed that hepatic
congestion caused by obstruction of hepatic venous out-
flow tract can lead to hepatic necrosis, fibrosis and cir-
rhosis, which contribute to the pathogenesis of HCC in
patients with BCS [24]. This idea is supported by our
findings of cirrhotic change in liver parenchyma adjacent
to HCC in all patients with HCC. In addition, theoccurrence of cirrhosis was significantly higher in pa-
tients with HCC than that in patients with benign nod-
ules, further suggesting that cirrhosis may contribute to
the development of HCC.
It has been reported that patients with long-standing
inferior vena cava block have a 70-fold higher risk of de-
veloping HCC than those with pure hepatic vein block
[3]. In agreement with this report, we found that pa-
tients with inferior vena cava block were more fre-
quently complicated with HCC than those with single
hepatic vein block. Patients with single hepatic vein
block were not associated with HCC in our study. In
addition, stricture of hepatic venous outflow tract (in 10
patients) was more frequently associated with HCC than
obstruction of hepatic venous outflow tract (in 4 pa-
tients). We also found that the frequency of occurrence
of portal vein invasion was significantly lower in HCC
patients with BCS than that in HCC patients with hepa-
titis, suggesting that extrahepatic metastases is less likely
to occur in HCC patients with BCS.
Imaging studies in combination with clinical informa-
tion are often essential for a definitive diagnosis of HCC,
and can help to distinguish it from other hypervascular
masses [25]. In this study, we found imaging features of
HCC in patients with BCS, which are useful to distin-
guish HCC from benign hypervascular regenerative
nodules. HCC in patients associated with BCS was
isointense or hypointense in nonenhanced CT images,
and exhibited heterogeneous enhancement on arterial
phase and washout on portal venous phase. Axial T1-
weighted images showed that all nodules exhibited ir-
regular and heterogeneous enhancement during the ar-
terial phase, and washout during the portal venous
phase. T2-weighted images showed that these nodules
were hyperintense or isointense. These imaging features
are consistent with previous reports in patients with
HCC [25-27]. In addition, the location, shape, size, num-
ber of nodules have a high values to distinguish HCC
from benign nodules [3,25]. Most nodules of HCC were
usually near the edge of liver, irregular, more than 3 cm
in diameter, heterogeneous mass and solitary (≤3 nod-
ules). Different and almost opposite features were found
in benign nodules.
The serum AFP level can be used for diagnosis and
screening of HCC [12]. An increase in AFP level (>20
μg/L) was found in 12 of 14 patients with HCC, but not
in any patients with benign nodules, suggesting that the
serum AFP level is valuable for the diagnosis of HCC. In
addition, the serum AFP level significantly declined after
TACE treatment, suggesting that the serum AFP level
can be used to evaluate the efficacy of TACE treatment.
Shin et al. suggested that HCC patients associated
BCS were susceptible to aggressive intervention such as
TACE [4]. In agreement with this report, we found that
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follow-up. In addition, angioplasty and stenting were
performed to treat hepatic vein and/or inferior vena cava
block in these patients. Elimination of hepatic vein and/
or inferior vena cava block can result in an improvement
of liver a reduction by reducing the hepatic sinusoidal pres-
sure, thus preventing the occurrence of HCC [1]. However,
since angioplasty and stenting are only performed in
nine patients in different ways, it remains unclear
whether angioplasty and stenting can reduce the occur-
rence of HCC, and whether angioplasty and stenting
can improve the effect of TACE. Until now, there is no
consensus about the methods and timing of the treat-
ment for HCC patients with BCS. Large cohort studies
are needed to confirm the values of these therapeutic
methods in the future.
The prognosis in patients with HCC remains poor be-
cause the high rate of tumor recurrence or the develop-
ment of new tumor [28,29]. TACE has been shown to
improve survival of patients with HCC in a randomized
control trial [16]. It has been reported that the 3- and
5-year survival rates of patients receiving TACE was
26-47% [16,17,30,31] and 16-26% [32-34], respectively.
Because of the low incidence of BCS patients with
HCC, no studies with a large patient population have
been investigated the long-term survival of BCS patients
with HCC receiving TACE. In a study of 20 HCC patients
with membranous obstruction of the inferior vena cava
who received TACE , the 3- and 5 year survival rate was
61% and 46%, respectively [9]. In the present study, all
patients survived during the mean follow-up period of
33.46 months (range, 2–71 months). However, since some
patients were not followed up for more than one year, the
survival rate was not determined in our study.Conclusions
In this study, we investigated the imaging features of
HCC and changes in the serum AFP level after TACE
treatment HCC patients associated with BCS. A single,
large, irregular nodule with a peripheral location appears
to be HCC. Inferior vena cava block and stricture of
hepatic venous outflow tract more frequently occur in
BCS patients with HCC. TACE is an effective treatment
of HCC in patients with BCS.Abbreviations
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